FibroBiologics (NASDAQ:FBLG) Earns Buy Rating from HC Wainwright

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock.

Several other research firms have also issued reports on FBLG. D. Boral Capital reiterated a “buy” rating and set a $16.00 target price on shares of FibroBiologics in a report on Friday, December 27th. Rodman & Renshaw began coverage on FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $13.00.

FibroBiologics Trading Up 0.6 %

Shares of FBLG stock opened at $1.73 on Thursday. The firm’s fifty day moving average price is $1.99 and its two-hundred day moving average price is $2.49. FibroBiologics has a 1 year low of $1.08 and a 1 year high of $17.75.

Hedge Funds Weigh In On FibroBiologics

A number of institutional investors have recently bought and sold shares of FBLG. Charles Schwab Investment Management Inc. lifted its position in shares of FibroBiologics by 5.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock valued at $215,000 after buying an additional 3,451 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in FibroBiologics in the 3rd quarter valued at $32,000. Jane Street Group LLC bought a new stake in FibroBiologics in the 3rd quarter valued at $37,000. Intech Investment Management LLC acquired a new stake in FibroBiologics during the 4th quarter valued at $25,000. Finally, Virtu Financial LLC bought a new position in FibroBiologics during the fourth quarter worth $30,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.